NASDAQ OMX

Data on Novel Humanized Models for Targeted Immunotherapy Development, a CrownBio Conference Talk on January 24th, 2018

Dela

SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will unveil data supporting use of its cost-effective, humanized drug target models at the Tumor Models Conference in San Francisco tomorrow, Wednesday, January 24th, 2018.

Humanized research tools are crucial to the development of target-specific immunotherapies like pembrolizumab and ipilimumab. To help improve research in this burgeoning field, CrownBio has developed a humanized platform that informs the preclinical pharmacology of targeted immunotherapies, including solutions for PD-1, PD-L1, OX40, and CD3E. Constituent models feature fully functional murine immunity with humanized drug targets that can be used in conjunction with syngeneic tumor cell lines engineered to express complementary humanized targets.

Compelling data will showcase the utility of CrownBio's humanized platform to comprehensively and reliably evaluate targeted immunotherapies, reduce cost of development and shorten experimental timelines.

"We are excited to share data on our innovative humanized models with industry at the Tumor Models Conference tomorrow in San Francisco," said Laurie Heilmann, CrownBio's Chief Business Officer. "Our expert scientists have built a revolutionary humanized platform that will help researchers discover and develop targeted immunotherapeutics for cancer faster and more cost-effectively."

Dr. Toni Jun, Director of Scientific Engagement at CrownBio, will present data on the characterization, validation, and application of PD-1, PD-L1, OX40, and CD3E models.

About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates. 

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. 
marketing@crownbio.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Medibio Corporate Health Extends Global Footprint Signing Contract with Jacobs Engineering25.5.2018 16:38Pressmeddelande

Jacobs, one of the world's largest engineering and environmental consultancy groups, has more than 70,000 employees globally SYDNEY, Australia and MINNEAPOLIS, May 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, today announced a significant contract for Medibio's Corporate Health product with Dallas, TX-based Jacobs Engineering across their Asia Pacific, Middle East, and European divisions. Through the Mental Health Check-In, companies can offer employees an end-to-end mental health program, direct to their devices, to see how the mind and body are tracking. It's a personalized, private, and objective way to see the unseeable: mental health issues in the workplace. Employees are provided the opportunity to confidentially check-in on their mental health and receive personalized confidential results from both an objective biometric screening in conjunction with a 12-minute subjective survey. Employers receive

LeoVegas warms up ahead of FIFA World Cup with launch of sportsbook 2.0 and new design25.5.2018 14:20Pressmeddelande

LeoVegas is conducting constant development to further improve the gaming experience with the launch of sportsbook 2.0 and a new design for Leovegas.com. It strengthens LeoVegas mobile position and increases the competitiveness within sports betting. "Our new design has been created to give our customers a better overview of all games in all product verticals," comments Gustaf Hagman, CEO of LeoVegas. "The design features a simplified and more intuitive experience, which is especially important in sport, where relevance and simplicity are key factors. On top of this we are launching a number of updates and expanding ownership of the sportsbook. Together this builds further on creating a world class gaming experience and is in line with our passion "Leading the way into the mobile future". This will give us the right conditions ahead of the World Cup, but it also represents a long-term springboard towards building the world's best mobile sportsbook". Improved sports betting experience L

LeoVegas värmer upp inför fotbolls VM och lanserar sportbok 2.0 med ny design25.5.2018 14:19Pressmeddelande

Det sker en ständig utveckling av LeoVegas och för att förbättra spelupplevelsen ytterligare lanseras nu sportbok 2.0 samt en ny design av LeoVegas.com. Det stärker LeoVegas mobila position och ökar konkurrenskraften inom sportsbetting. "Vår nya design är skapad för att ge våra kunder en bättre överblick för alla spel inom samtliga produktvertikaler. Designen ger en förenklad och mer intuitiv upplevelse vilket är särskilt viktigt inom sport där relevans och enkelhet är nyckelfaktorer. Utöver det lanserar vi ett flertal uppdateringar samt ökar ägarskapet av sportboken. Tillsammans bygger det vidare på att skapa en spelupplevelse i världsklass och går i linje med vår passion "Leading the way to the mobile future". Detta ger oss rätt förutsättningar inför VM men de är också ett långsiktigt avstamp till att bygga världens bästa mobila sportbok. säger Gustaf Hagman, CEO LeoVegas. Förbättrad sportupplevelse LeoVegas har nu ägarskap över flera sidor som leverantören Kambi tidigare hade kontro

VIRGIN PULSE ANNOUNCES INDUSTRY-LEADING GDPR COMPLIANCE25.5.2018 14:00Pressmeddelande

Virgin Pulse Extends the GDPR's Strong Data Privacy Rights to All Clients and Members Across the Globe PROVIDENCE, R.I., May 25, 2018 (GLOBE NEWSWIRE) -- Virgin Pulse, the leading global provider of digital employee health, wellbeing and engagement solutions, today announced that it has achieved compliance with the EU General Data Protection Regulation (GDPR) for the Virgin Pulse platform. The company has also appointed Associate Counsel Beatrice Botti as Data Protection Officer (DPO) to oversee the Virgin Pulse privacy program. With this achievement, Virgin Pulse leads the market as the first company in the wellbeing and engagement industry to fully meet the comprehensive standards of the new GDPR data privacy law. The company has completed a thorough review of its internal data collection, storage and handling processes and implemented enhancements to achieve GDPR compliance and give all Virgin Pulse customers and members greater control over their personal data. The GDPR is the firs

Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45Pressmeddelande

CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH

Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30Pressmeddelande

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum